2026 Speakers

Ana C. Garrido-Castro

Ana C. Garrido-Castro

Medical Oncologist | Dana-Farber Cancer Institute

"Dr. Garrido-Castro is a medical oncologist specialized in breast cancer at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School. Her research efforts focus on the development of novel therapeutics for patients with breast cancer, with particular emphasis on the treatment of triple-negative breast cancer. Dr. Garrido-Castro is the Director of Triple-Negative Breast Cancer Research in the Division of Breast Oncology at Dana-Farber, and leads clinical trials studying immunotherapy, antibody drug conjugates, and targeted therapy approaches for patients with breast cancer. Dr. Garrido-Castro also serves as Associate Director for Breast Oncology Education overseeing breast cancer educational initiatives at Dana-Farber. Dr. Garrido-Castro’s research has been supported by the NIH/NCI, Breast Cancer Research Foundation (BCRF), Susan G. Komen, Conquer Cancer Foundation of ASCO, Triple-Negative Breast Cancer Foundation, METAvivor, Terri Brodeur Breast Cancer Foundation, and Breast Cancer Alliance. She is the recipient of the 2023 Conquer Cancer – Triple Negative Breast Cancer Foundation Advanced Clinical Research Award and is a past recipient of the BCRF Marion R. Wright Award for Scientific Excellence."

Anna Kirby

Anna Kirby

Consultant Clinical Oncologist | The Royal Marsden and Institute of Cancer Research

Professor Anna Kirby is a Consultant Clinical Oncologist specialising in the treatment of patients with breast cancer. She leads research into novel breast radiotherapy techniques at The Royal Marsden and Institute of Cancer Research, London. She is Chief Investigator of the FAST-Forward Boost Trial, Technical Radiotherapy Lead for the PARABLE Proton Trial, and was Chief Investigator on the HeartSpare trials facilitating implementation of heart-sparing breast radiotherapy in the UK. She was President of the European Society of Radiation Oncology (ESTRO) from 2022-24.

Don Dizon

Don Dizon

Chief of the Hematology and Oncology Service Line | Tufts Medicine

Don S. Dizon is the Service Line Chief of Hematology-Oncology at Tufts Medicine and is the Jane F. Desforges Endowed Chair in Hematology and Oncology and Professor of medicine at Tufts University. He is a medical oncologist specializing in breast and pelvic malignancies, survivorship particularly as it pertains to sexual health for men and women with cancer, patient engagement, and social media. He grew up on the Pacific Island of Guam, and completed undergraduate and medical school at the University of Rochester in New York. He trained in Internal Medicine at Yale New-Haven Hospital and completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in NYC. He is the 2025 recipient of the Excellence in Equity Award from the American Society of Clinical Oncology. In addition to his academic appointments, he is the Inaugural Vice Chair of Membership and Accrual for SWOG Oncology Research Network and is currently the Editor-In-Chief at CA: A Cancer Journal for Clinicians, the flagship journal of the American Cancer Society. Follow him on Bluesky, Instagram, Facebook, and TikTok @drdonsdizon.

Faye Lim

Faye Lim

Senior Consultant Radiation Oncologist | National Cancer Centre Singapore

Dr. Faye Lim is a Senior Radiation Oncologist at the National Cancer Centre Singapore who specializes in both Breast and Gastrointestinal Cancers. She trained at the Mount Vernon Cancer Centre and the University College London Hospitals in the United Kingdom. She has a special interest in the use and optimization of proton therapy and is the Clinical Lead for proton therapy in the treatment of breast cancer.

Francois-Clement Bidard

Francois-Clement Bidard

Professor of Medicine in the Department of Medical Oncology | Institut Curie & UVSQ/Université Paris-Saclay

François-Clément Bidard, MD PhD, is a Professor of Medicine in the Department of Medical Oncology at Institut Curie & UVSQ/Université Paris-Saclay. He is also the co-coordinator of breast cancer research at Institut Curie, the #1 center for breast cancer in France, and, since 2023, the vice-Chair of the French Breast Cancer research group UCBG (Unicancer). His clinical work primarily focuses on breast cancers. His research aims at characterizing the cellular mechanisms involved in the metastatic process, with a focus on blood biomarkers (circulating tumor cells, circulating tumor DNA etc.). He teaches medical students at the Simone Veil Faculty of Science (UVSQ/Université Paris-Saclay), as well as residents and students in the Department of Medical Oncology (Institut Curie); he is coordinating the ""Breast Diseases"" postgraduate training at UVSQ/Université Paris-Saclay.

Gary Deng

Gary Deng

Professor of Medicine, Associate Director | University of California Irvine

Dr. Gary Deng is Professor of Medicine and the Samueli Endowed Chair in Integrative Oncology at the University of California, Irvine (UCI). He serves as an Associate Director of the UCI Chao Family Comprehensive Cancer Center, Director of Clinical Affairs at the Susan Samueli Integrative Health Institute, and Program Director of Integrative Oncology at UCI Health. His professional expertise lies in an integrative, whole-person approach to health—supporting patients across the continuum of cancer prevention, treatment, and survivorship.

Hee Jeong Kim

Hee Jeong Kim

Breast Cancer Specialist | Asan Medical Center

A Ph.D. and M.S. graduate of Ulsan University, Prof. Kim Hee Jeong completed her M.D. from Cheon Buk National University. She is currently a Professor at University of Ulsan and previously was a Visiting Doctor at Dana Farber Harvard Medical School (2017-2019) and Dana Farber Cancer Institute, Memorial Sloan Kettering Cancer Center (2010). She has published the Journal of Clinical Oncology in "Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial" and published 190 SCI and SCIE papers.

Irene Teo

Irene Teo

Principal Psychologist | National Cancer Centre Singapore

Dr. Irene Teo is a principal clinical psychologist at the Dept of Psychosocial Oncology at the National Cancer Centre Singapore. She works with patients through their adjustment to cancer and into cancer survivorship using psychological and behavioural techniques. She is also research faculty at the Lien Centre for Palliative Care, Duke-NUS and is committed to improving psychosocial oncology care.

Lisa Webber

Lisa Webber

Senior Consultant Obstetrics ＆ Gynaecology | Singapore General Hospital

Dr. Lisa is a consultant gynaecologist and RCOG accredited subspecialist in reproductive medicine. She has been working in CARE at SGH since April 2023, on sabbatical from Imperial College Healthcare NHS Trust. She graduated from Oxford University Medical School in 1991 and later obtained her PhD at Imperial College London, studying the development of preantral follicles in the normal and polycystic ovary with Prof Steve Franks. This was the foundation of her interest in disorders of ovarian function. She trained in reproductive medicine at University College Hospital London and later worked there as a senior consultant before returning to St Mary’s Hospital at Imperial. She is experienced in managing menopause and premature ovarian insufficiency (iatrogenic and spontaneous) and co-chaired the original 2015 ESHRE guideline on POI. She also provides all forms of medically assisted reproduction and manages the non-fertility aspects of PCOS and functional hypothalamic amenorrhoea.

Ma Jun

Ma Jun

Medical Oncologist | National Cancer Centre Singapore

Dr Ma Jun is a consultant breast medical oncologist at the National Cancer Centre Singapore. She has a clinical focus on breast cancer treatment and a special interest in young women with breast cancer.

Matteo Lambertini

Matteo Lambertini

Adjunct Professor and Consultant in Medical Oncology | University of Genova – Enet Ospedaliero Opsedali Galliera, Genoa, Italy

Dr. Matteo Lambertini is associate professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Thanks to the support of the European Society for Medical Oncology (ESMO), he has completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients". He is a member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embriology (ESHRE) and the Italian Association of Medical Oncology (AIOM).

Nur Fadhlina Abdul Satar

Nur Fadhlina Abdul Satar

Clinical Oncologist | Pantai Hospital, Kuala Lumpur

Dr Nur Fadhlina is an active member of Department of Clinical Oncology University Malaya, being awarded the Excellence Service Award in 2023 by University of Malaya. She is also the Principal Investigator for industry led international clinical trials in Head and Neck and Breast cancers, winning CIC Award for Highest Research Grant procured in 2021. She has actively collaborated with local researchers and industry, publishing results in international journals such as Clinical Oncology, Frontiers in Nutrition and Diagnostics. Her research work has been presented internationally as posters in ASCO, ESMO Asia, ESTRO and ASCOMOS. She won the Japan Society Medical Oncology Rising Star in Asia Workshop Award, and presented work on nasopharyngeal cancer in Fukuoka, Japan in 2023.

Tira Tan

Tira Tan

Senior Consultant in the Department of Breast and Gynaecology, Division of Medical Oncology; Deputy Director of Research and Deputy Director of Clinical Trials and Epidemiology | National Cancer Centre Singapore, Duke-NUS Medical School

Dr Tira J Tan is a breast oncologist and clinical investigator who serves as Deputy Director of Research and Deputy Director of Clinical Trials and Epidemiology at the National Cancer Centre Singapore. She holds the position of Clinical Assistant Professor at Duke-NUS Medical School and Senior Consultant in the Department of Breast and Gynaecology, Division of Medical Oncology. Dr Tan's clinical expertise centres on aggressive breast cancer subtypes, particularly triple-negative breast cancer (TNBC) and metastatic disease. Her research focuses on integrating multi-omic approaches, including genomics, transcriptomics, and proteomics, with clinical outcomes to advance precision oncology for diverse patient populations. She is particularly committed to addressing ethnic and racial disparities in cancer research, ensuring that Asian and other underrepresented populations are included in cutting-edge cancer studies. Dr Tan has made significant contributions to the field through her leadership of investigator-initiated trials, including the international DORA Phase II study evaluating olaparib with or without durvalumab in platinum-pretreated advanced TNBC. Her research portfolio encompasses novel therapeutic approaches, from microbial ecosystem therapeutics to adenoviral vector immunotherapy, with findings published in high-impact journals including Clinical Cancer Research, Nature Communications, and Annals of Oncology. As an author of influential reviews and book chapters, Dr Tan has helped shape the understanding of TNBC biology and therapeutics. Her work spans from defining molecular subtypes to exploring emerging immunotherapies and targeted agents. Through her role in multi-institutional collaborations and molecular tumour boards, she continues to bridge molecular discovery with clinical application, ultimately working towards more effective and equitable treatments for patients with breast cancer.